Inscripta Inc. (now Manus Bio Inc.)
The University of Colorado Connection
Groundbreaking CRISPR gene editing technology developed in the laboratory of Ryan Gill (frm. CU Boulder Chemical and Biological Engineering) led to the formation of genome engineering company Muse Biotech in 2015. Muse later became Inscripta, which raised over $400 million in venture capital funding.
Inscripta merged with Manus Bio in 2025 to create a leading company in industrial biotechnology. Visit the Manus Bio Website
Funding Status and Investment Opportunities
- Industry Applications: Biotech, Genomics, Manufacturing
- Funding Stage: Exit
- Contact for Investment Inquiries: Manus Website
In the News
- Manus and Inscripta merge to create a leader in industrial biomanufacturing (2025)
- Inscripta is reimagining what the synthetic biology company of the future will be (2023)
- The world's first fully automated benchtop digital genome engineering platform from CU spinout Inscripta is here (2021)
- Inscripta wins Company of the Year at Colorado BioScience Association's Annual Awards Celebration (2020)
- Single cell writing may unlock CRISPR’s full potential (2019)
This page was last updated on Sept. 8, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.